A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge.

Tytuł:: A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge.
Autorzy:: Park JE; Laboratory of Veterinary Public Health, College of Veterinary Medicine, Chungnam National University, Daejeon, 34134, Republic of Korea. .; Research Institute of Veterinary Research, Chungnam National University, Daejeon, 34134, Republic of Korea. .
Kim JH; Laboratory of Veterinary Public Health, College of Veterinary Medicine, Chungnam National University, Daejeon, 34134, Republic of Korea.
Park JY; Laboratory of Veterinary Infectious Diseases, College of Veterinary Medicine, Chungnam National University, Daejeon, 34134, Republic of Korea.
Jun SH; Electron Microscopy & Spectroscopy Team, Korea Basic Science Institute, Cheongju, Chungcheongbukdo, 28119, Republic of Korea.
Shin HJ; Laboratory of Veterinary Infectious Diseases, College of Veterinary Medicine, Chungnam National University, Daejeon, 34134, Republic of Korea. .; Research Institute of Veterinary Research, Chungnam National University, Daejeon, 34134, Republic of Korea. .
Źródło:: Virology journal [Virol J] 2022 Jun 27; Vol. 19 (1), pp. 112. Date of Electronic Publication: 2022 Jun 27.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: [London] : BioMed Central, 2004-
MeSH Terms:: Coronavirus Infections*
Middle East Respiratory Syndrome Coronavirus*/genetics
Vaccines, Virus-Like Particle*/genetics
Viral Vaccines*/genetics
Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; Cryoelectron Microscopy ; Mammals ; Mice ; Mice, Inbred C57BL ; Spike Glycoprotein, Coronavirus/genetics
References:: Vaccine. 2012 Dec 17;31(1):58-83. (PMID: 23142589)
Cells. 2021 Apr 09;10(4):. (PMID: 33918600)
Oncotarget. 2017 Feb 21;8(8):12686-12694. (PMID: 27050368)
Nat Microbiol. 2020 Dec;5(12):1598-1607. (PMID: 33106674)
EMBO J. 1996 Apr 15;15(8):2020-8. (PMID: 8617249)
Lancet Infect Dis. 2013 Sep;13(9):752-61. (PMID: 23891402)
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3119-E3128. (PMID: 28348219)
Cell. 2022 Mar 3;185(5):847-859.e11. (PMID: 35139340)
Emerg Infect Dis. 2013 Mar;19(3):456-9. (PMID: 23622767)
mBio. 2012 Nov 20;3(6):. (PMID: 23170002)
J Nanobiotechnology. 2021 Feb 25;19(1):59. (PMID: 33632278)
J Virol. 2008 Nov;82(22):11318-30. (PMID: 18753196)
N Engl J Med. 2015 Feb 26;372(9):846-54. (PMID: 25714162)
mBio. 2020 Apr 7;11(2):. (PMID: 32265331)
Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89. (PMID: 6754243)
Emerg Microbes Infect. 2019;8(1):516-530. (PMID: 30938227)
Cell. 2020 Oct 1;183(1):158-168.e14. (PMID: 32979941)
Curr Protoc Microbiol. 2015 May 01;37:15E.2.1-9. (PMID: 26344219)
N Engl J Med. 2014 Aug 28;371(9):828-35. (PMID: 25162889)
Vaccine. 2008 Feb 6;26(6):797-808. (PMID: 18191004)
N Engl J Med. 2012 Nov 8;367(19):1814-20. (PMID: 23075143)
Viruses. 2012 Jun;4(6):1011-33. (PMID: 22816037)
J Virol. 1992 Nov;66(11):6695-705. (PMID: 1383568)
Transl Res. 2022 Apr;242:20-37. (PMID: 34801748)
FEBS Lett. 2004 Oct 8;576(1-2):174-8. (PMID: 15474033)
Expert Rev Vaccines. 2016 Sep;15(9):1123-34. (PMID: 26985862)
Vaccine. 2014 Sep 22;32(42):5496-502. (PMID: 25131727)
J Virol. 2002 May;76(10):4987-99. (PMID: 11967315)
Acta Biochim Pol. 2014;61(3):531-9. (PMID: 25273564)
Vaccines (Basel). 2020 Mar 20;8(1):. (PMID: 32244935)
Vaccine. 2007 Apr 12;25(15):2832-8. (PMID: 17092615)
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12262-12267. (PMID: 27791014)
J Virol. 1992 Feb;66(2):956-65. (PMID: 1309922)
Emerg Infect Dis. 2014 Jun;20(6):1012-5. (PMID: 24857749)
Emerg Infect Dis. 2020 Feb;26(2):191-198. (PMID: 31961300)
Contributed Indexing:: Keywords: Immunogenicity; MERS-CoV; Protective efficacy; Vaccine; Virus-like particle
Substance Nomenclature:: 0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (Spike Glycoprotein, Coronavirus)
0 (Vaccines, Virus-Like Particle)
0 (Viral Vaccines)
Entry Date(s):: Date Created: 20220627 Date Completed: 20220629 Latest Revision: 20220801
Update Code:: 20240105
PubMed Central ID:: PMC9235161
DOI:: 10.1186/s12985-022-01844-9
PMID:: 35761402
: Czasopismo naukowe

Pełny tekst

Background: Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans, with a case fatality rate of approximately 35%, thus posing a considerable threat to public health. The lack of approved vaccines or antivirals currently constitutes a barrier in controlling disease outbreaks and spread.
Methods: In this study, using a mammalian expression system, which is advantageous for maintaining correct protein glycosylation patterns, we constructed chimeric MERS-CoV virus-like particles (VLPs) and determined their immunogenicity and protective efficacy in mice.
Results: Western blot and cryo-electron microscopy analyses demonstrated that MERS-CoV VLPs were efficiently produced in cells co-transfected with MERS-CoV spike (S), envelope, membrane and murine hepatitis virus nucleocapsid genes. We examined their ability as a vaccine in a human dipeptidyl peptidase 4 knock-in C57BL/6 congenic mouse model. Mice immunized with MERS VLPs produced S-specific antibodies with virus neutralization activity. Furthermore, MERS-CoV VLP immunization provided complete protection against a lethal challenge with mouse-adapted MERS-CoV and improved virus clearance in the lung.
Conclusions: Overall, these data demonstrate that MERS-CoV VLPs have excellent immunogenicity and represent a promising vaccine candidate.
(© 2022. The Author(s).)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja